title: Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report.
abstract: Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652-1654, 2017.
authors.affiliation: NYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Benedict
authors.affiliation: Phoniatrics Unit, Department of Otorhinolaryngology, Alexandria University School of Medicine, Alexandria, Egypt.
authors.forename: Rania M
authors.initials: RM
authors.lastname: Abdou
authors.affiliation: NYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
authors.forename: Gregory R
authors.initials: GR
authors.lastname: Dion
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine, New York, New York, U.S.A.
authors.forename: Peak
authors.initials: P
authors.lastname: Woo
authors.affiliation: NYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
authors.forename: Ryan C
authors.initials: RC
authors.lastname: Branski
authors.affiliation: NYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
authors.forename: Milan R
authors.initials: MR
authors.lastname: Amin
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001044:Aphonia / Q000139:chemically induced; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007827:Laryngitis / Q000139:chemically induced* / Q000188:drug therapy; D007828:Laryngoscopy; D011241:Prednisone / Q000008:administration & dosage; D014833:Voice Quality / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C571059:alirocumab; D011241:Prednisone
keywords: Larynx; adverse effect; alirocumab; laryngeal lesion; monoclonal antibody